Sarepta Therapeutics Inc (NASDAQ:SRPT) target price upped to $83.00, reported earlier today by Royal Bank Of Canada
- Updated: September 19, 2016
Just yesterday Sarepta Therapeutics Inc (NASDAQ:SRPT) traded 91.30% higher at $51.30. Sarepta Therapeutics Inc’s 50-day moving average is $26.16 and its 200-day moving average is $20.47. The last stock price close is up 163.13% from the 200-day average, compared to the S&P 500 Index which has decreased -0.01% over the same time period. 29,541,278 shares of SRPT traded, up from ann average trading volume of 2,328,380.
Stating a possible upside of 0.62%, Royal Bank Of Canada upped the target price of Sarepta Therapeutics Inc (NASDAQ:SRPT) to $83
Previously on 7/22/2016, Needham released a statement on Sarepta Therapeutics Inc(NASDAQ:SRPT) raised the target price from $20.00 to $26.00. At the time, this indicated a possible upside of 0.15%.
Recent Performance Chart:
A total of 13 firms have released a research note on SRPT. Three firms rate the stock a strong buy, one firm rate the company a buy, five firms rate the company a hold, four analysts rate the company to underperform, and finally one brokeragerate the stock as sell with a one year target of $20.77
With a market capitalization of $0.0, Sarepta Therapeutics Inc has a one-year low of $8.00 and a one-year high of $56.18 with a PE ratio of 0.
Brief Synopsis On Sarepta Therapeutics Inc (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company’s lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, and is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.